Log In
Print
BCIQ
Print
Print this Print this
 

SynGEM

  Manage Alerts
Collapse Summary General Information
Company Mucosis B.V.
DescriptionRespiratory synctial virus vaccine comprised of bacterium-like-particle (BLP) based Mimopath technology carrying trimeric Fusion proteins
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentPreclinical
Standard IndicationRespiratory syncytial virus (RSV)
Indication DetailsPrevnt respiratory syncytial virus (RSV) infections
Regulatory Designation
Partner Changchun BCHT Biotechnology Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today